Dr. Dana M. Chase, a medical oncologist specializing in gynecologic cancers, dives into the management of recurrent endometrial cancer. She discusses how biomarker profiles, like MMR status, influence treatment decisions involving carboplatin, paclitaxel, and dostarlimab. The conversation highlights insights from the RUBY trial, showcasing significant survival improvements with dostarlimab in various patient groups. Dr. Chase also stresses the growing incidence of endometrial cancer, its symptoms, and the vital role of clinical trials in shaping future therapies.
